Today news
About the same in other media
Moderna/Merck begin late-stage study of mRNA cancer vaccine
Reading now: 648
(Reuters) — Moderna (NASDAQ:MRNA) and drugmaker Merck have started a late-stage study to evaluate their experimental mRNA-based cancer vaccine in combination with cancer therapy Keytruda, the companies said on Wednesday.
The companies will study the safety and efficacy of the vaccine-Keytruda combination in patients with a type of skin cancer, compared to Keytruda alone.
Global recruitment for the trial has begun, with the first patients being enrolled in Australia, the companies said in a joint release.
Shares of Moderna rose 1% in premarket trading.
Read more on investing.comAbout this in other media
Russia to begin CBDC trials with 13 banks cointelegraph.com /1 year ago
Crunchyroll adds new titles to AVoD slate livemint.com /1 year ago
Caterpillar, Merck rise premarket; Pfizer, JetBlue and ZoomInfo fall investing.com /1 year ago
Show more
The website fvbb.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
